Souhaitez-vous accéder aux communiqués récents ?

Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.

Se Connecter À Un Compte Lecteur Créer Un Compte Lecteur

10 juin 2019 08h05 HE | Source: Diasome Pharmaceuticals, Inc.

Diasome’s Hepatocyte Directed Vesicle (HDV) Technology Met Primary Endpoint in Phase 2b Trial in Type 1 Diabetes

Hepatic safety also confirmed over six months of treatment with mealtime liver targeted insulin Company focused on Phase 3 initiation in 2020 CLEVELAND, June 10, 2019 (GLOBE NEWSWIRE) -- Diasome...
29 mai 2019 10h05 HE | Source: Diasome Pharmaceuticals, Inc.

Diasome Announces Presentations at the American Diabetes Association’s 79th Scientific Sessions

CLEVELAND, May 29, 2019 (GLOBE NEWSWIRE) -- Diasome Pharmaceuticals, Inc., today announced upcoming presentations of an abstract highlighting data from the company’s Phase 2b ISLE-1 clinical trial...
28 mars 2019 10h03 HE | Source: Diasome Pharmaceuticals, Inc.

Diasome Announces First Patient Enrolled in Phase 2 Study of Hepatocyte Directed Vesicle Nanotechnology for People with Type 1 Diabetes

CLEVELAND, March 28, 2019 (GLOBE NEWSWIRE) -- Diasome Pharmaceuticals, Inc., a clinical stage biopharmaceutical company developing hepatocyte directed vesicle (HDV) nanotechnology that can be added...
14 févr. 2019 10h04 HE | Source: Diasome Pharmaceuticals, Inc.

Diasome Provides Company Update

CLEVELAND, Feb. 14, 2019 (GLOBE NEWSWIRE) -- Diasome Pharmaceuticals, Inc., a clinical stage biopharmaceutical company developing hepatocyte directed vesicle (HDV) nanotechnology as an insulin...